Mylan received FDA approval for generic versions of AstraZeneca's hypertension treament, Plendil extended-release tablets. Mylan said it received approval for 2.5 mg, 5 mg, and 10 mg doses and already started shipping the product.
Pfizer received approval to market its anti-tumor drug/kinase inhibitor Sutent capsule 12.5 mg (sunitinib malate) in Japan. Sutent is indicated for gastrointestinal stromal tumor after failure of imatinib treatment due to resistance and for renal cell carcinoma not indicated for curative resection and metastatic renal cell carcinoma. Sutent was approved in the US in January 2006.